Literature DB >> 18055674

Stability of antibiotics in portable pumps used for bronchial superinfection: guidelines for prescribers.

Nicolas Arlicot1, Gaël Y Rochefort, Deborah Schlecht, Fabien Lamoureux, Sophie Marchand, Daniel Antier.   

Abstract

OBJECTIVES: The aims of this study were (1) to collect data on the stability of antibiotics in portable pumps for the treatment of bronchial superinfection in patients with cystic fibrosis and (2) to provide guidelines for prescribers.
METHODS: The stability over 72 hours, in portable pumps stored at 35 degrees C, of piperacillin plus tazobactam, ticarcillin plus clavulanic acid, cefsulodin, cefepime, and aztreonam was checked at 3 different concentrations. Stability was assessed through visual examination, pH measurements, and direct measurements of drug concentrations by using high-performance liquid chromatography. All parameters were measured at time 0, time 0 plus 24 hours, and time 0 plus 72 hours.
RESULTS: Degradation rates for penicillin plus beta-lactamase inhibitor combinations remained <10% at time 0 plus 24 hours for all drugs, but the rate for piperacillin reached 12% for the highest concentration tested. The cephalosporins cefepime and cefsulodin had significant respective degradation rates of 18% and 28% at time 0 plus 24 hours and 60% and 68.5% at time 0 plus 72 hours, which were linked to the storage temperature. Aztreonam seemed to be stable over 72 hours.
CONCLUSIONS: This work provides data on drug stability that were lacking, allowing recommendations for physicians to optimize the safety and efficacy of antibiotic treatment of patients with cystic fibrosis. Piperacillin plus tazobactam and ticarcillin plus clavulanic acid infusions must be limited to 24 hours, and patients receiving cefepime or cefsulodin must wear a cold pack close to the ambulatory drug-delivery device during the infusion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055674     DOI: 10.1542/peds.2007-0630

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

Review 1.  Systematic review of stability data pertaining to selected antibiotics used for extended infusions in outpatient parenteral antimicrobial therapy (OPAT) at standard room temperature and in warmer climates.

Authors:  Stephen John Perks; Cassie Lanskey; Niechole Robinson; Tilley Pain; Richard Franklin
Journal:  Eur J Hosp Pharm       Date:  2019-06-20

2.  Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.

Authors:  William A Prescott; Allison E Gentile; Jerod L Nagel; Rebecca S Pettit
Journal:  P T       Date:  2011-11

3.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

4.  An Engineered sgsh Mutant Zebrafish Recapitulates Molecular and Behavioural Pathobiology of Sanfilippo Syndrome A/MPS IIIA.

Authors:  Alon M Douek; Mitra Amiri Khabooshan; Jason Henry; Sebastian-Alexander Stamatis; Florian Kreuder; Georg Ramm; Minna-Liisa Änkö; Donald Wlodkowic; Jan Kaslin
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

5.  Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement.

Authors:  E Samara; T F Moriarty; L A Decosterd; R G Richards; E Gautier; P Wahl
Journal:  Bone Joint Res       Date:  2017-05       Impact factor: 5.853

6.  Protocol for a randomised crossover trial to evaluate patient and nurse satisfaction with electronic and elastomeric portable infusion pumps for the continuous administration of antibiotic therapy in the home: the Comparing Home Infusion Devices (CHID) study.

Authors:  Jodie G Hobbs; Melissa K Ryan; Brett Ritchie; Janet K Sluggett; Andrew J Sluggett; Lucy Ralton; Karen J Reynolds
Journal:  BMJ Open       Date:  2017-07-31       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.